The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy

Cancer Lett. 2016 Sep 1;379(2):245-52. doi: 10.1016/j.canlet.2015.06.023. Epub 2015 Jul 17.

Abstract

The ubiquitin-proteasome system (UPS) is a complicated tightly controlled system in charge of degrading 80-90% of proteins, and is central to regulating cellular function and keeping protein homeostasis. Therefore, the components of UPS attract considerable attention as potential targets for hepatocellular carcinoma (HCC) therapy. The clinical success of bortezomib in multiple myeloma and mantle cell lymphoma patients has set the precedent for therapeutically targeting this pathway. This review will provide an overview of the UPS in HCC and the current status of therapeutic strategies.

Keywords: Hepatocellular carcinoma; Inhibitor; Treatment; Ubiquitin–proteasome system.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Bortezomib / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / enzymology*
  • Carcinoma, Hepatocellular / pathology
  • Drug Design
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / enzymology*
  • Liver Neoplasms / pathology
  • Molecular Targeted Therapy
  • Oligopeptides / therapeutic use
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors / therapeutic use*
  • Protein Processing, Post-Translational / drug effects*
  • Ubiquitination

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Oligopeptides
  • Proteasome Inhibitors
  • Bortezomib
  • carfilzomib
  • Proteasome Endopeptidase Complex